Cargando…

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents

Eradicating HIV-1 infection is difficult because of the reservoir of latently infected cells that gets established soon after infection, remains hidden from antiretroviral drugs and host immune responses, and retains the capacity to reignite infection following the cessation of treatment. Drugs call...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Vipul, Dixit, Narendra M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833289/
https://www.ncbi.nlm.nih.gov/pubmed/29451894
http://dx.doi.org/10.1371/journal.pcbi.1006004
_version_ 1783303458493825024
author Gupta, Vipul
Dixit, Narendra M.
author_facet Gupta, Vipul
Dixit, Narendra M.
author_sort Gupta, Vipul
collection PubMed
description Eradicating HIV-1 infection is difficult because of the reservoir of latently infected cells that gets established soon after infection, remains hidden from antiretroviral drugs and host immune responses, and retains the capacity to reignite infection following the cessation of treatment. Drugs called latency-reversing agents (LRAs) are being developed to reactivate latently infected cells and render them susceptible to viral cytopathicity or immune killing. Whereas individual LRAs have failed to induce adequate reactivation, pairs of LRAs have been identified recently that act synergistically and hugely increase reactivation levels compared to individual LRAs. The maximum synergy achievable with LRA pairs is of clinical importance, as it would allow latency-reversal with minimal drug exposure. Here, we employed stochastic simulations of HIV-1 transcription and translation in latently infected cells to estimate this maximum synergy. We incorporated the predominant mechanisms of action of the two most promising classes of LRAs, namely, protein kinase C agonists and histone deacetylase inhibitors, and quantified the activity of individual LRAs in the two classes by mapping our simulations to corresponding in vitro experiments. Without any adjustable parameters, our simulations then quantitatively captured experimental observations of latency-reversal when the LRAs were used in pairs. Performing simulations representing a wide range of drug concentrations, we estimated the maximum synergy achievable with these LRA pairs. Importantly, we found with all the LRA pairs we considered that concentrations yielding the maximum synergy did not yield the maximum latency-reversal. Increasing concentrations to increase latency-reversal compromised synergy, unravelling a trade-off between synergy and efficacy in LRA combinations. The maximum synergy realizable with LRA pairs would thus be restricted by the desired level of latency-reversal, a constrained optimum we elucidated with our simulations. We expect this trade-off to be important in defining optimal LRA combinations that would maximize synergy while ensuring adequate latency-reversal.
format Online
Article
Text
id pubmed-5833289
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58332892018-03-23 Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents Gupta, Vipul Dixit, Narendra M. PLoS Comput Biol Research Article Eradicating HIV-1 infection is difficult because of the reservoir of latently infected cells that gets established soon after infection, remains hidden from antiretroviral drugs and host immune responses, and retains the capacity to reignite infection following the cessation of treatment. Drugs called latency-reversing agents (LRAs) are being developed to reactivate latently infected cells and render them susceptible to viral cytopathicity or immune killing. Whereas individual LRAs have failed to induce adequate reactivation, pairs of LRAs have been identified recently that act synergistically and hugely increase reactivation levels compared to individual LRAs. The maximum synergy achievable with LRA pairs is of clinical importance, as it would allow latency-reversal with minimal drug exposure. Here, we employed stochastic simulations of HIV-1 transcription and translation in latently infected cells to estimate this maximum synergy. We incorporated the predominant mechanisms of action of the two most promising classes of LRAs, namely, protein kinase C agonists and histone deacetylase inhibitors, and quantified the activity of individual LRAs in the two classes by mapping our simulations to corresponding in vitro experiments. Without any adjustable parameters, our simulations then quantitatively captured experimental observations of latency-reversal when the LRAs were used in pairs. Performing simulations representing a wide range of drug concentrations, we estimated the maximum synergy achievable with these LRA pairs. Importantly, we found with all the LRA pairs we considered that concentrations yielding the maximum synergy did not yield the maximum latency-reversal. Increasing concentrations to increase latency-reversal compromised synergy, unravelling a trade-off between synergy and efficacy in LRA combinations. The maximum synergy realizable with LRA pairs would thus be restricted by the desired level of latency-reversal, a constrained optimum we elucidated with our simulations. We expect this trade-off to be important in defining optimal LRA combinations that would maximize synergy while ensuring adequate latency-reversal. Public Library of Science 2018-02-16 /pmc/articles/PMC5833289/ /pubmed/29451894 http://dx.doi.org/10.1371/journal.pcbi.1006004 Text en © 2018 Gupta, Dixit http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gupta, Vipul
Dixit, Narendra M.
Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
title Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
title_full Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
title_fullStr Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
title_full_unstemmed Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
title_short Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
title_sort trade-off between synergy and efficacy in combinations of hiv-1 latency-reversing agents
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833289/
https://www.ncbi.nlm.nih.gov/pubmed/29451894
http://dx.doi.org/10.1371/journal.pcbi.1006004
work_keys_str_mv AT guptavipul tradeoffbetweensynergyandefficacyincombinationsofhiv1latencyreversingagents
AT dixitnarendram tradeoffbetweensynergyandefficacyincombinationsofhiv1latencyreversingagents